Celltech looks a real tonic

INVESTORS attracted by the potential in the biotechnology industry but worried about the risks should look at Celltech. The group has excellent management and a broadly based pipeline of potential new drugs which could yield blockbuster returns. It is not over-dependent on any single project. At the same time it has plenty of cash in the balance sheet, a profitable and dramatically expanding manufacturing business, and alliances with established industry giants which ensure that it is at no risk of running out of money for the foreseeable future.

Rivals are increasingly taking note of Celltech as a model of how a biotechnology company should be managed in the 1990s. In the United States, by contrast, many smaller biotech companies have funding problems. This changing perception has been reflected in a share price up from 219p, when I wrote about the group last year, to 286p currently, against a flotation price of 250p in December 1993.

Investors should not be put off by the rise that has already taken place. Despite the cautious approach, Celltech is playing for high stakes and the bull market in the shares may have only just begun. Fair-value models for 1997, making the admittedly considerable assumption that there are no great disappointments in clinical trials between now and then, could see the shares worth more than £l0, even though the group is unlikely to be seriously profitable much before the end of the decade.

One factor in the transformation of Celltech's prospects is a new management team. Dr Peter Fellner and Dr David Bloxham, respectively group chief executive and chief executive of Celltech Therapeutics (the drug development arm), both ex-Roche, were brought in to give the group focus. They have transformed it. But the real pay-off will come as we approach the 10- year anniversary of their arrival, when we will know if any of the trial drugs is a winner.

The next couple of years could be crucial. The group has two particularly promising compounds: CDP 571 for the treatment of rheumatoid arthritis, inflammatory bowel disease and septic shock; and CDP 840 for the treatment of asthma. Some idea of how seriously these compounds are taken in the industry comes from the partnerships Celltech has formed to develop them. Bayer is committed to make payments (known as milestone payments) to the group of £29m to fund the development of CDP 571. Milestone payments of up to £31.5m, payable over a five-year period, have been committed by Merck on CDP 840. The group has alliances with four large companies with milestone payments of £62m in total, of which £l3.6m has been paid so far. The deal is that Celltech does the initial research. The huge cost of further development and marketing is then handled by the companies. Yet Celltech can still expect a share of between 25 and 45 per cent of the profits on its products.

A common element in all Celltech's compounds is their relation to human monoclonal antibodies and the immune response. In effect, the group, with a research staff of 185 based in Slough, has become a world-recognised centre of excellence. This has other benefits. First, the group is a leading manufacturer of antibodies for its own and other companies' use. Last year this division made profits of £2m on £l4.2m of sales, despite considerable disruption at the factory. Profits are also understated by up to £2m because much of the production is supplied at cost within the group. Expansion is under way in both this country and New Hampshire in the US. Profits from this division could be £5m to £l0m by the end of the decade.

A worldwide surge of interest in the therapeutic use of antibodies could also generate royalties for the group, because many companies will be using Celltech's technology. First fruits are being seen with a new drug launched by Eli Lilly, which could generate royalties for the group of more than $5m (£3m) in a few years if sales reach $250m. An educated guess is that as other human antibody-based compounds come on stream, sales could reach $lbn, generating perhaps $20m of annual profit for Celltech.

Celltech's current market capitalisation of £203m could be justified by its human antibody manufacturing and licensing income, even if none of its third- party-funded drug development programmes is successful. Yet prospects look good or the big drug companies would not be providing such chunky payments. If just one of these drugs is a winner the rewards could be spectacular. The shares look an attractive speculative play with far less downside than is usual with biotechnology investments.

A 1930 image of the Karl Albrecht Spiritousen and Lebensmittel shop, Essen. The shop was opened by Karl and Theo Albrecht’s mother; the brothers later founded Aldi
Arts and Entertainment
Standing the test of time: Michael J Fox and Christopher Lloyd in 'Back to the Future'
filmA cult movie event aims to immerse audiences of 80,000 in ‘Back to the Future’. But has it lost its magic?
Arts and Entertainment
Flora Spencer-Longhurst as Lavinia, William Houston as Titus Andronicus and Dyfan Dwyfor as Lucius
theatreThe Shakespeare play that proved too much for more than 100 people
exclusivePunk icon Viv Albertine on Sid Vicious, complacent white men, and why free love led to rape
Arts and Entertainment
Stir crazy: Noel Fielding in 'Luxury Comedy 2: Tales from Painted Hawaii'
comedyAs ‘Luxury Comedy’ returns, Noel Fielding on why mainstream success scares him and what the future holds for 'The Boosh'
Life and Style
Flow chart: Karl Landsteiner discovered blood types in 1900, yet scientists have still not come up with an explanation for their existence
lifeAll of us have one. Yet even now, it’s a matter of debate what they’re for
Arts and Entertainment
'Weird Al' Yankovic, or Alfred Matthew, at the 2014 Los Angeles Film Festival Screening of
musicHis latest video is an ode to good grammar. But what do our experts think he’s missed out?
New Real Madrid signing James Rodríguez with club president Florentino Perez
sportColombian World Cup star completes £63m move to Spain
Hotel Tour d’Auvergne in Paris launches pay-what-you-want
travelIt seems fraught with financial risk, but the policy has its benefits
Arts and Entertainment
booksThe best children's books for this summer
Life and Style
News to me: family events were recorded in the personal columns
techFamily events used to be marked in the personal columns. But now Facebook has usurped that
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Programme Director - Conduct Risk - London

£850 - £950 per day: Orgtel: Programme Director - Conduct Risk - Banking - £85...

Business Analyst (Agile, SDLC, software)

£45000 - £50000 Per Annum + excellent benefits: Clearwater People Solutions Lt...

Finance Manager - Bank - Leeds - £300/day

£250 - £300 per day + competitive: Orgtel: Finance Manager - Accountant - Bank...

Compliance Officer - CF10, CF11, Compliance Oversight, AML, FX

£100000 - £120000 per annum + BONUS + BENEFITS: Harrington Starr: A leading fi...

Day In a Page

Noel Fielding's 'Luxury Comedy': A land of the outright bizarre

Noel Fielding's 'Luxury Comedy'

A land of the outright bizarre
What are the worst 'Word Crimes'?

What are the worst 'Word Crimes'?

‘Weird Al’ Yankovic's latest video is an ode to good grammar. But what do The Independent’s experts think he’s missed out?
Can Secret Cinema sell 80,000 'Back to the Future' tickets?

The worst kept secret in cinema

A cult movie event aims to immerse audiences of 80,000 in ‘Back to the Future’. But has it lost its magic?
Facebook: The new hatched, matched and dispatched

The new hatched, matched and dispatched

Family events used to be marked in the personal columns. But now Facebook has usurped the ‘Births, Deaths and Marriages’ announcements
Why do we have blood types?

Are you my type?

All of us have one but probably never wondered why. Yet even now, a century after blood types were discovered, it’s a matter of debate what they’re for
Honesty box hotels: You decide how much you pay

Honesty box hotels

Five hotels in Paris now allow guests to pay only what they think their stay was worth. It seems fraught with financial risk, but the honesty policy has its benefit
Commonwealth Games 2014: Why weight of pressure rests easy on Michael Jamieson’s shoulders

Michael Jamieson: Why weight of pressure rests easy on his shoulders

The Scottish swimmer is ready for ‘the biggest race of my life’ at the Commonwealth Games
Some are reformed drug addicts. Some are single mums. All are on benefits. But now these so-called 'scroungers’ are fighting back

The 'scroungers’ fight back

The welfare claimants battling to alter stereotypes
Amazing video shows Nasa 'flame extinguishment experiment' in action

Fireballs in space

Amazing video shows Nasa's 'flame extinguishment experiment' in action
A Bible for billionaires

A Bible for billionaires

Find out why America's richest men are reading John Brookes
Paranoid parenting is on the rise - and our children are suffering because of it

Paranoid parenting is on the rise

And our children are suffering because of it
For sale: Island where the Magna Carta was sealed

Magna Carta Island goes on sale

Yours for a cool £4m
Phone hacking scandal special report: The slide into crime at the 'News of the World'

The hacker's tale: the slide into crime at the 'News of the World'

Glenn Mulcaire was jailed for six months for intercepting phone messages. James Hanning tells his story in a new book. This is an extract
We flinch, but there are degrees of paedophilia

We flinch, but there are degrees of paedophilia

Child abusers are not all the same, yet the idea of treating them differently in relation to the severity of their crimes has somehow become controversial
The truth about conspiracy theories is that some require considering

The truth about conspiracy theories is that some require considering

For instance, did Isis kill the Israeli teenagers to trigger a war, asks Patrick Cockburn